Chemistry:IHCH-7162

From HandWiki

IHCH-7162, also known as centpyraquin or compound 69-183, is a serotonin receptor modulator related to the partial ergolines.[1][2] It is a serotonin 5-HT1A receptor agonist and a mixed modulator of the serotonin 5-HT2A receptor, acting as a weak partial agonist of G protein signaling and as an antagonist of β-arrestin2 recruitment.[2] The drug has antipsychotic-like, CNS depressant, and antihypertensive effects in animals.[3][4][5][6] IHCH-7172 was developed by researchers in India and first described by the 1970s[1][3][4][5][6] before being studied and described further by a Chinese team in 2024.[2]

See also

  • IHCH-7179
  • Centpropazine

References

  1. 1.0 1.1 "Medicinal chemistry research in India". Prog Med Chem. Progress in Medicinal Chemistry 22: 243–266. 1985. doi:10.1016/s0079-6468(08)70232-7. ISBN 978-0-444-80668-0. PMID 2873624. 
  2. 2.0 2.1 2.2 "Flexible scaffold-based cheminformatics approach for polypharmacological drug design". Cell 187 (9): 2194–2208.e22. April 2024. doi:10.1016/j.cell.2024.02.034. PMID 38552625. 
  3. 3.0 3.1 "Antihypertensive and central nervous system depressant properties of 3-(gamma-p-fluorobenzoyl propyl) 2,3,4,4a,5,6-hexahydro-1(H)-pyrazino(1,2-a) quinoline hydrochloride (compound 69-183, centpyraquin)". Experientia 29 (12): 1529–1530. December 1973. doi:10.1007/BF01943898. PMID 4203916. 
  4. 4.0 4.1 "Pharmacological studies on 3-[gamma-(p-fluorobenzoyl)propyl]-2,3,4,4a,5,6-hexahydro-1-(H)-pyrazino (1,2-a) quinoline (compound 69/183). Part I: Hypotensive activity". Arzneimittelforschung 28 (7): 1087–91. 1978. PMID 114185. 
  5. 5.0 5.1 "Pharmacological studies on 3-[gamma-(p-fluorobenzoyl)propyl]-2,3,4,4a,5,6-hexahydro-1 (H)-pyrazino(1,2-a) quinoline hydrochloride (compound 69/183). Part II: Effect on cardiac dynamics". Arzneimittelforschung 28 (7): 1092–1095. 1978. PMID 582695. 
  6. 6.0 6.1 "Pharmacological studies on 3-[gamma-(p-fluorobenzoyl)propyl]-2,3,4,4a,5,6-hexahydro-1-(H)-pyrazino ]1,2-a] quinoline hydrochloride (compound 69/183). Part III: Assessment of tranquillising activity". Arzneimittelforschung 28 (8): 1403–1406. 1978. PMID 37855.